Blackstone, Carlyle, KKR Eye $11 Billion Buyout

Apr 10 2013 | 10:28am ET

A trio of private equity giants are circling laboratory supplies and genetic testing company Life Technologies in what could be among the largest buyouts of the year.

The Blackstone Group, the Carlyle Group and Kohlberg Kravis Roberts, along with Singapore's sovereign wealth fund, are preparing an $11 billion bid for Life. The four were in talks late last night on terms, even after the deadline for bids passed. Should the private equity group manage to find the needed equity, Life would likely accept a bid after the deadline, according to Reuters.

The p.e. group will have to compete with a bid from Thermo Fisher Scientific, which submitted its offer yesterday.

The p.e. group as it exists is actually a merger of what could have been two competing consortia: Blackstone, Carlyle and Temasek Holdings had been working with TPG Capital, which has since dropped out, while KKR was working on a deal with other partners, who also backed out.


In Depth

Q&A: TCA Fund Management's Bob Press on Small-Cap Private Equity

Aug 25 2016 | 8:55pm ET

The emergence of private credit as a replacement for traditional bank financing...

Lifestyle

Kiawah: Island Reversal

Aug 24 2016 | 9:59pm ET

Looking for real estate investments but the typical real estate fare isn’t cutting...

Guest Contributor

Old Hill Partners: Embrace Illiquidity

Aug 9 2016 | 2:39pm ET

The age-old financial concept that higher yields are the result of higher risk and...